Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1753-1769

  Prakash, Chandra ^a   Johnson, Kim A ^a   Schroeder, Clinton M ^a   Potchoiba, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CATECHOL; DRUG METABOLITE; GLUCURONIDE; LASOFOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; LIQUID CHROMATOGRAPHY; LONG EVANS RAT; MALE; MAXIMUM PLASMA CONCENTRATION; METHYLATION; MONKEY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; SPECIES DIFFERENCE; SPLEEN; TANDEM MASS SPECTROMETRY; UVEA; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTROGEN RECEPTOR MODULATORS; FECES; FEMALE; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION;

RATTUS;

EID: 50049094480     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021808     Document Type: Article

References (32)

1. Baillie TA, Cayen MN, Fouda HG, Gerson RJ, Gree JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
2. Bolton JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160.
3. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evan DC, et al. (2002) Cytochrome P-450 3A4 mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914.
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, and Lane D (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 289:3243-3253.
5. Cosman F, Lindsay R (1999) Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20:418-434.
6. Cummings SR, Eckert S., Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. (1999) The effects of raloxifene on risk of breast cancer in postmenopausal women: results from more randomized trial. J Am Med Assoc 281:2189-2197.
7. Daniels JS, Espina R, Cao K, Yuan H, Lin J, Diamond S, Johnson B, Rodgers J, Prakash S, Unger S, et al. (2007) Species-specific, P450- and sulfotransferase -mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkey. Chem Res Toxicol 20:1709-1717.
8. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. (1998) Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowl Project P-1 Study. J Natl Cancer Inst 87:1681-1685.
9. Gambacciani M and Ciaponi M (2000) Postmenopausal osteoporosis management. Curr Opin Obstet Gynecol 12:189-197.
10. Gennari L, Merlotti D, Martini G, and Nuti R (2006) Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Invest Drugs 15: 1091-1103.
11. Hodis NH, Mack WJ, Azen SP, Lobo RA, Shoupe D, and Mahrer PR (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349:535-545.
12. Kamel A and Prakash C (2006) High performance liquid chromatography/ atmospheric pressure ionization /tandem Mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology studies. Curr Drug Metab 7:837-852.
13. Ke HZ, Foley GL, Simmons HA, Shen V, and Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145:1996-2005.
14. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, and Simmons HA (1998) Effects of lasofoxifene, a new nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139:2068-2076.
15. Larsson B and Tjalve H (1979) Studies on the mechanism of drug-binding to melanin. Biochem Pharmacol 28:1181-1187.
16. Leblanc B, Jezequel S, Davies T, Hanton G, and Taradach C (1998) Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 28:124-132.
17. Luisetto G, Zangari M, Tizian L, Nardi A, Ramazzina E, and Adami S (1993) Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner 22:9-25.
18. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, and Lasser NL (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534.
19. Mattiuz EL, Ponsler GD, Barbuch RJ, Wood PG, Mullen JH, Shugert RL, Li Q, Wheeler WJ, Kuo F, Conrad PC, et al. (2003) Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab Dispos 31:88-97.
20. Monks TJ, Hanzlik RP, Cohen GM, Ross D, and Graham DG (1992) Contemporary issues in toxicology: quinone chemistry and toxicity. Toxicol Appl Pharmacol 112:2-16.
21. Potchoiba MJ, Tensfeldt TG, Nocerini MR, and Silber BM (1995) A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther 272:953-962.
22. Potchoiba MJ, West M, and Nocerini MR (1998) Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab Dispos 26:272-277.
23. Prakash C, Johnson K, and Gardner M (2008) Disposition of lasofoxifene, a next generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab Dispos 36:1218-1226.
24. Prakash C, Shaffer C, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369.
25. Riggs BL, Khosla S, and Melton LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
26. Rosati RL, Da Silva JP, Cameron KO, Thompson DD, Ke HZ, and Toler SM (1998) Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41:2928-2931.
27. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288:321-333.
28. Sowers MR, Finkelstein JS, Hettinger B, Bondarenko I, Neer RM, and Cauley JA (2003a) The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 14:44-52.
29. Sowers MR, Greendale GA, Bondarenko I, Finkelstein JS, Cauley JA, and Neer RM (2003b) Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 14:191-197.
30. Ullberg S (1977) The technique of whole-body autoradiography cryosectioning of large specimens. Sci ToolsLKB J 1-29.
31. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kopparberg C, and Baird A (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. J Am Med Assoc 289:2673-2684.
32. Witt DM and Lousberg TR (1997) Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 31:745-755.